Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-12-04
2009-12-29
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S049000
Reexamination Certificate
active
07638502
ABSTRACT:
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
REFERENCES:
patent: 3553192 (1971-01-01), Kumar
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4382925 (1983-05-01), De Clercq et al.
patent: 4424211 (1984-01-01), Jones et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4681933 (1987-07-01), Chu et al.
patent: 4841039 (1989-06-01), Chu et al.
patent: 4957924 (1990-09-01), Beauchamp
patent: 5079235 (1992-01-01), Purifoy et al.
patent: 5356882 (1994-10-01), Walker et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5792773 (1998-08-01), Chu et al.
patent: 6022876 (2000-02-01), Chu et al.
patent: 6177436 (2001-01-01), Spector et al.
patent: 6274589 (2001-08-01), Chu et al.
patent: 2002/0025296 (2002-02-01), Knaus et al.
patent: 0486477 (2005-03-01), None
patent: WO 95/07287 (1995-03-01), None
patent: 96/16183 (1996-05-01), None
patent: WO 96/13512 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 00/09531 (2000-02-01), None
patent: 01/06986 (2001-02-01), None
Jones et al. J. Chem. Soc. Perkin Trans. I (1987), pp. 457-464.
Reefschlager et al. Pharmaceutical Research (1987), vol. 4, pp. 200-206.
Goodchild et al. J. Med. Chem. (1983), vol. 26, pp. 1252-1257.
Boorstein et al. Cancer Research (1989), vol. 49, pp. 1509-1514.
Anisimova, E., et al., (1984) “Effects of n-butyrate and phorbol ester (TPA) on induction of EBV antigens and cell differentiation” Arch. Virol., 81, 223-237.
Ansari, A., et al., (1999) “The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses” J. Virol., 73(4), 3284-3291.
Balzarini, J., et al., (1989) “Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2′-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2′-deoxyuridine”, J. Med. Chem., 32, 1861-1865.
Barba, D., et al. (1994) “Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors”, Proc. Natl. Acad. Sci. USA, 91, 4348-52.
Basnak, I., et al., (1998) Nucleosides and Nucleotides, 17, 29-38.
Beauchamp L.M., et al., (1988) “Effect of acyclic pyrimidines related to 0-[(1,3-dihycroxy-2-propoxy)methyl]guanine on herpesviruses”, J. Med. Chem., 31, 144-149.
Belen'Kil, M.S., et al., (1994) “Multiple drug effect analysis with confidence interval”, Antiviral Res., 25, 1-11.
Brand, K., et al., “Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors”, Cancer Gene Therap, 4, 9-16; 1997.
Cannon, J.S., et al., (1999) “Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir” J. Virol., 73(6), 4786-793.
Caruso, M., et al., (1993) “Regression of established macroscopic liver metastases after in-situ transduction of a suicide gene” Proc. Natl. Acad. Sci. USA, 90, 7024-7028.
Chen, S.H., et al., (1994) “Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo” Proc. Natl. Acad. Sci. USA, 91, 3054-3057.
Cheng, Y.C., et al., (1983) “Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type I”, Proc. Natl., Acad. Sci. USA, 80, 2767-2770.
Choi, Y., et al., (2000) “Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes virus”, J. Med. Chem., 43, 2538-2546.
Chou, T. C., et al., (1984), “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors”, Adv. Enzyme Regul., 22, 27-55.
Culver K.W., et al. (1992) “In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors”, Science, 256, 1550-1552.
Daniel, P., et al., (1989) “Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts”, Clin. Chim. Acta, 181, 255-263.
Datta et al., (1980) “Acyclovir inhibition of Epstein-Barr virus replication”, Proc. Natl., Acad. Sci. USA, 77, 5163-5166.
Datta et al., (1981) “Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid”, Virol., 114, 52-59.
Dyson, M.R., et al., (1991) “The synthesis and antiviral activity of some 4′-thio-2′-deoxy nucleoside analogues”, J. Med. Chem., 34, 2782-2786.
Emery, V.C., et al., (2000) “Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy”, Proc. Natl. Acad. Sci., 97(14), 8039-44.
Gustafson, E.A., et al., (1998) “The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow specificity compared to herpes simplex virus type 1 thymidine kinase”, Antimicrob. Agents Chemother., 42(11), 2923-31.
Hamel, W., et al., (1996) “Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells”, Cancer Res., 56, 2697-2702.
Herdewijn, P., et al. (1985) “Synthesis and antiviral activity of the carbocyclic analogues (E)-5-(2-halovinyl)-2′-deoxyuridines and (E)-5-(2-halovinyl)-2′-deoxycytidines”, J. Med. Chem. 28, 550-555.
Hoffer, M., (1960) “α-Thymidin”, Chem. Ber., 93, 2777-2781.
Holy, A. (1972) “Nucleic acid components and their analogues, CLIII. Preparation of 2′-deoxy-L-ribonucleosides of the pyrimidine series”, Coll. Czech. Chem. Commun., 37, 4072-4086.
Imamura, K., et al. (1997) “Synthesis and in vitro evaluation of 5-closo-and 5-nido-orthocarboranyluridines as boron carriers”, Bull, Chem. Soc. Jpn., 70, 3103-3110.
Jones, A.S., et al. (1979) “The synthesis of the potent anti-herpes virus agent, E-5-(2-bromoviny1)-2′-deoxyuridine and related compounds”, Tetrahedron Lett., 45, 4415-4418.
Kam, B.L. et al. (1981) “Carbocyclic sugar amines: synthesis and stereochemistry of racemic α- and β-carbocyclic ribofuranosylamine, carbocyclic lyxofuranosylamine, and related compounds”, J. Org. Chem., 46, 3268-3272.
Kim, J.H., et al., (1995) “Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents” Int. J. Radiat. Oncol. Biol. Phys., 33, 861-868.
Lin, J. C., et al. (1987) “Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication”, Antimicrob. Agents & Chemotherapy, 31(9), 1431-1433.
Lin, J. C., et al. (1988) “Anti-Human Immunodeficiency Virus agent 3′-azido-3′-deoxythymidine inhibits replaction of Epstein-Barr virus”, Antimicrob. Agents & Chemotherapy, 32(2), 265-267.
Lin, J. C., et al., (1988) “Comparison of two bromovinyl nucleoside analogs, 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2′-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication”, Antimicrob. Agents Chemo., 32(7), 1068-1072.
Lin, J. C., et al. (1984) “Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus”, J. Virol., 50(1), 50-55.
Lin, J. C. (1999) “Antiviral therapy for Epstein-Barr virus: the challenge ahead”, Recent Res. Develop. Antimicrob. Agents and Chemother., 3, 191-223.
Lin, J. S., et al., (1999) “Structure-activity relationships of L-dioxolane uracil nucleo
Fingeroth Joyce D.
Gustafson Erik
Schinazi Raymond F.
Shi Junxing
Beth Israel Deaconess Medical Center
Emory University
Lewis Patrick T
Merchant & Gould P,C,
Pharmasset, Inc.
LandOfFree
Treatment of EBV and KHSV infection and associated abnormal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of EBV and KHSV infection and associated abnormal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of EBV and KHSV infection and associated abnormal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4097292